India sees 21% dip in TB cases but has 25% of new patients globally

India achieved a significant 21% reduction in tuberculosis cases between 2015 and 2024, with incidence falling from 237 to 187 per lakh population, a decline rate twice the global average. Despite this progress, the nation still represents 25% of all new global TB cases. This improvement, driven by intensified government initiatives, advanced diagnostics, and a rise in treatment coverage to over 92% with a 90% success rate, suggests enhanced public health infrastructure and disease management, potentially impacting long-term healthcare expenditure and workforce productivity.

Analysis

India has demonstrated significant progress in combating tuberculosis, achieving a 21% reduction in cases between 2015 and 2024, with incidence falling from 237 to 187 per lakh population. This decline rate is twice the global average, as reported by the WHO Global TB Report 2025, positioning India as a leader in disease reduction among high-burden nations. Despite this impressive progress, India still accounts for a substantial 25% of all new global TB cases, underscoring the ongoing scale of the public health challenge.

The success is primarily attributed to intensified efforts under the TB Mukt Bharat Abhiyan, which includes innovative case-finding strategies and the adoption of advanced diagnostic technologies. Treatment coverage has dramatically increased from 53% in 2015 to over 92% in 2024, leading to a significant reduction of "missing" TB cases from 15 lakh to less than one lakh. A treatment success rate of 90%, exceeding the global average of 88% and with no major rise in multidrug-resistant TB, highlights the effectiveness of these public health interventions.

These developments signal a strengthening of India's public health infrastructure and disease management capabilities. Improved health outcomes could positively impact long-term workforce productivity and potentially reduce healthcare expenditure related to TB, fostering a more stable economic environment. This trend may also indicate emerging opportunities within the healthcare technology and diagnostics sectors that have supported this progress.

Key Decisions for Investors

• Investors should consider the long-term positive implications for India's human capital and economic productivity stemming from improved public health metrics.
• Evaluate potential investment opportunities in Indian healthcare technology, diagnostics, and pharmaceutical companies that are instrumental in disease management and prevention.
• Monitor government healthcare spending and policy initiatives, as sustained support for public health programs like TB Mukt Bharat Abhiyan could drive further sector growth and innovation.